Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;5:k3519.

Article  Google Scholar 

Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. The Lancet. 2021;398(10305):1075–90.

Article  CAS  Google Scholar 

Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, et al. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol. 2008;179(1):156–62.

Article  PubMed  Google Scholar 

Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9.

Article  CAS  PubMed  Google Scholar 

Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.

Article  CAS  PubMed  Google Scholar 

Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate-specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma. Cancer [Internet]. 1998;82(11):2256–61.

Article  CAS  PubMed  Google Scholar 

Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet [Internet]. 2020;395(10231):1208–16.

Article  CAS  Google Scholar 

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856–63.

Article  PubMed  PubMed Central  Google Scholar 

Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res [Internet]. 2021;27(13):3674–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, et al. Update from PSMA-SRT Trial NCT03582774: a randomized phase 3 imaging trial of prostate-specific membrane antigen positron emission tomography for salvage radiation therapy for prostate cancer recurrence powered for clinical outcome. Eur Urol Focus [Internet]. 2021;7(2):238–40.

Article  PubMed  Google Scholar 

Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856–63.

Article  PubMed  PubMed Central  Google Scholar 

Oprea-Lager DE, Gontier E, García-Cañamaque L, Gauthé M, Olivier P, Mitjavila M, et al. [18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study. Eur J Nucl Med Mol Imaging. 2023;50(11):3439–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res [Internet]. 2021;27(13):3674–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tilki D, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol [Internet]. 2024; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283824023066

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol [Internet]. 2024; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283824022541

Kane CJ, Amling CL, Johnstone PAS, Pak N, Lance RS, Thrasher JB, et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology. 2003;61(3):607–11.

Article  PubMed  Google Scholar 

Calais J, Armstrong WR, Kishan AU, Booker KM, Hope TA, Fendler WP, et al. Update from PSMA-SRT Trial NCT03582774: a randomized phase 3 imaging trial of prostate-specific membrane antigen positron emission tomography for salvage radiation therapy for prostate cancer recurrence powered for clinical outcome. Eur Urol Focus [Internet]. 2021;7(2):238–40.

Article  PubMed  Google Scholar 

Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric 68 Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nuclear Med [Internet]. 2017;58(12):1962–8.

Article  CAS  Google Scholar 

Crocetto F, Russo G, Di Zazzo E, Pisapia P, Mirto BF, Palmieri A, et al. Liquid biopsy in prostate cancer management—current challenges and future perspectives. Cancers (Basel). 2022;14(13):3272.

Article  CAS  PubMed  Google Scholar 

Carrasco R, Ingelmo-Torres M, Gómez A, Trullas R, Roldán FL, Ajami T, et al. Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer. Int J Mol Sci. 2022;23(19):63.

Article  Google Scholar 

Green EA, Li R, Albiges L, Choueiri TK, Freedman M, Pal S, et al. Clinical utility of cell-free and circulating tumor DNA in kidney and bladder cancer: a critical review of current literature. Eur Urol Oncol. 2021;4(6):893–903.

Article  PubMed  Google Scholar 

Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, et al. Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA). Eur Urol. 2018;74(3):283–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12(7):e1006162.

Article  PubMed  PubMed Central  Google Scholar 

Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):63.

Article  Google Scholar 

Chen E, Cario CL, Leong L, Lopez K, Márquez CP, Chu C, et al. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. Sci Rep. 2021;11(1):5040.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lapin M, Oltedal S, Tjensvoll K, Buhl T, Smaaland R, Garresori H, et al. Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer. J Transl Med. 2018;16(1):300.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamamoto Y, Uemura M, Nakano K, Hayashi Y, Wang C, Ishizuya Y, et al. Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma. Oncotarget. 2018;9(29):20467–75.

Article  PubMed  PubMed Central  Google Scholar 

de González ACJ, Casanueva-Eliceiry S, Soler-Perromat A, Fuster D, Pastor V, Reguart N, et al. Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients. Eur J Nucl Med Mol Imaging [Internet]. 2021;48(11):3631–42.

Article  Google Scholar 

Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol [Internet]. 2023;83(5):405–12.

Article  CAS  PubMed  Google Scholar 

Kluge K, Einspieler H, Haberl D, Spielvogel C, Stoiber S, Vraka C, et al. Examining the relationship and prognostic significance of cell-free DNA levels and the PSMA-positive tumor volume in men with prostate cancer: a retrospective-prospective [68 Ga]Ga-PSMA-11 PET/CT Study. J Nuclear Med [Internet]. 2024;65(1):63–70.

Article  CAS  Google Scholar 

Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, et al. Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393–6.